Schwann cell dysfunction contributes to diabetic wound pathology which is partially ameliorated by oncostatin M treatment

This study demonstrates that Schwann cell dysfunction impairs diabetic wound healing by disrupting the injury-induced response, but therapeutic administration of the Schwann cell-derived factor oncostatin M (OSM) can partially rescue this pathology by enhancing epidermal proliferation, angiogenesis, and nerve regeneration.

The Gist

The Big Picture: A Broken Construction Site

Imagine your skin is a bustling construction site. When you get a cut, your body sends in a specialized crew to fix the damage. This crew includes:

• Bricklayers (skin cells) to rebuild the surface.
• Plumbers (blood vessels) to bring in supplies.
• Electricians (nerves) to restore sensation.

In a healthy person, this crew works in perfect harmony. But in people with diabetes, the construction site often gets stuck. The building never finishes, leading to chronic, non-healing wounds that can become dangerous.

This paper asks a specific question: Who is the foreman that tells the crew what to do, and why is the foreman missing in diabetic wounds?

The Missing Foreman: Schwann Cells

The researchers discovered that the "foreman" is a type of cell called a Schwann cell.

• What they usually do: Normally, when you get a cut, these Schwann cells (which usually live inside your nerves) wake up, leave their nerve homes, and rush into the wound. They act like a traffic controller, shouting instructions to the bricklayers and plumbers to start working hard. They also secrete a special "growth juice" (chemical signals) that tells everyone to multiply and repair the damage.
• What happens in Diabetes: In diabetic mice (a model for human diabetes), the researchers found that these Schwann cell foremen are asleep, confused, or just not showing up. Because the foreman is missing, the bricklayers and plumbers don't know what to do. The result? The wound stays open, the skin stays thin, and the nerves don't grow back.

The Magic Signal: Oncostatin M (OSM)

The researchers looked at what these healthy Schwann cells usually shout to the rest of the crew. They found a specific chemical signal called Oncostatin M (OSM).

Think of OSM as a super-charged megaphone message.

• In a healthy wound, the Schwann cells blow the whistle, and OSM tells the skin cells to multiply and the blood vessels to grow.
• In the diabetic wounds, this megaphone was silent because the Schwann cells were gone.

The Experiment: Giving the Wound a Megaphone

To test if this signal was the key, the researchers took diabetic mice with open wounds and gave them a dose of OSM directly into the wound.

The Results were like magic:

1. Faster Closing: The wounds closed much faster than the untreated ones.
2. Thicker Skin: The new skin was stronger and thicker (like a better-built wall).
3. More Blood Flow: New blood vessels grew in quickly (the plumbing was fixed).
4. Nerves Returned: The nerves started growing back into the wound area (the electricity was restored).

Essentially, by adding the "megaphone message" (OSM) back into the wound, they tricked the body into thinking the foreman was there, and the construction crew got to work immediately.

Why This Matters

This study is a big deal for a few reasons:

• It solves a mystery: It explains why diabetic wounds are so hard to heal. It's not just about bad blood flow; it's about the nerve cells (Schwann cells) failing to send the right instructions.
• It offers a new treatment: Instead of trying to fix the whole body's diabetes, doctors might one day be able to just spray a wound with OSM (or a drug that mimics it) to jumpstart the healing process.
• It connects nerves and skin: It shows that your nerves and your skin are best friends. If the nerves are unhappy, the skin can't heal.

The Bottom Line

In simple terms: Diabetes makes the "nerve foremen" go on strike, leaving the wound repair crew confused and idle. The researchers found that giving the wound a specific chemical signal (OSM) wakes the crew up, gets the construction moving again, and helps the wound heal much faster.

This opens the door for new, targeted therapies that could help millions of people with chronic diabetic wounds finally close their sores and heal properly.

Technical Summary

1. Problem Statement

Chronic diabetic wounds represent a significant clinical burden, often leading to ulcers and limb amputation. While the mechanisms of impaired healing are multifactorial (involving vascular insufficiency and persistent inflammation), the specific role of peripheral neuropathy and Schwann cell (SC) dysfunction remains poorly defined.

• The Gap: Although nerves are known to be essential for normal wound repair, and diabetic peripheral neuropathy (DPN) correlates with higher ulcer risk, the contribution of SCs (the glial cells supporting peripheral nerves) to the failure of diabetic wound healing is not well understood.
• The Hypothesis: The authors hypothesize that diabetes disrupts the injury-induced activation and dedifferentiation of Schwann cells, leading to a deficit in the paracrine trophic signals necessary for tissue repair. They further investigate whether supplementing a specific SC-derived factor, Oncostatin M (OSM), can rescue these deficits.

2. Methodology

The study utilized a combination of in vivo mouse models, histological analysis, and transcriptomic data mining.

• Animal Model:
  • Subjects: db/db mice (leptin receptor-deficient, Type 2 diabetes model) and db/+ littermate controls.
  • Wounding: 6-mm full-thickness excisional wounds created on the dorsal skin.
  • Treatment: In the therapeutic arm, db/db mice received bilateral wounds. One wound was treated intradermally with 200 ng Oncostatin M (OSM) on days 0, 2, 4, and 7; the contralateral wound received PBS (vehicle).
• Histological & Immunofluorescence Analysis:
  • Markers Used:
    • Schwann Cells: S100β (total SCs), p75NTR (dedifferentiated/activated SCs).
    • Proliferation: Ki67 (general), EdU incorporation (specifically for SC proliferation).
    • Axons: βIII-tubulin.
    • Angiogenesis: CD31 (endothelial cells).
  • Morphometrics: Wound closure rates, wound width/area, and epidermal/dermal thickness were quantified via H&E staining and digital imaging.
• Transcriptomic Analysis:
  • Bulk RNA-seq: Re-analysis of existing data (ENA: PRJEB22372) from FACS-purified SCs from wounded vs. uninjured skin to identify upregulated trophic factors.
  • Single-cell RNA-seq (scRNA-seq): Re-analysis of existing data (GSE142471) to map the expression of OSM receptors (Osmr and Il6st) across various wound-resident cell populations (keratinocytes, fibroblasts, vascular cells).
• Statistical Analysis: 2-way ANOVA for group comparisons (diabetic vs. control, OSM vs. PBS) and wound closure rates; paired Student's t-tests for specific cellular quantifications.

3. Key Contributions

1. Identification of SC Deficit in Diabetes: The study provides quantitative evidence that diabetic wounds exhibit a profound reduction in both total and dedifferentiated Schwann cells compared to non-diabetic controls.
2. Mechanistic Link to Trophic Support: The authors link the SC deficit to a lack of specific paracrine signaling, identifying Oncostatin M (OSM) as a key factor upregulated by activated SCs during normal repair.
3. Therapeutic Validation: The study demonstrates that exogenous administration of OSM can partially rescue the healing phenotype in diabetic mice, acting as a "mimetic" for the missing SC signal.
4. Broad Receptor Distribution: Through scRNA-seq, the authors mapped OSM receptors to multiple cell types in the wound bed (keratinocytes, fibroblasts, vascular cells), suggesting OSM acts as a master regulator coordinating epithelial, mesenchymal, and vascular repair.

4. Key Results

A. Impaired Healing and SC Dysfunction in db/db Mice

• Kinetics: db/db mice showed significantly delayed wound closure (still open at 21 days vs. healed by 10 days in controls), larger wound areas, and reduced dermal/epidermal thickness.
• Cellular Proliferation: Diabetic wounds showed significantly reduced cell proliferation (EdU+ cells) in the dermis.
• Neuropathy & SC Loss:
  • Re-innervation: Significantly reduced density of βIII-tubulin+ axons in diabetic wounds.
  • SC Quantification: A dramatic reduction in S100β+ (total) and p75NTR+ (dedifferentiated) Schwann cells in diabetic wounds compared to controls.
  • SC Proliferation: Fewer proliferating (EdU+) Schwann cells were found in diabetic wounds, indicating a failure of the SCs to activate and migrate into the wound bed.

B. Transcriptomic Identification of OSM

• Upregulation: Bulk RNA-seq of activated SCs revealed significant upregulation of Osm (along with Pdgfc, Lif, Ccl2) during wound healing.
• Receptor Mapping: scRNA-seq showed that OSM receptors (Osmr and Il6st) are widely expressed on keratinocytes, fibroblasts, and vascular-associated cells (pericytes/smooth muscle cells). Injury further upregulated these receptors in specific subsets, indicating a broad potential for OSM signaling during repair.

C. Therapeutic Effects of OSM Treatment

• Accelerated Closure: OSM-treated diabetic wounds were 18% smaller at day 4 and 45% smaller at day 9 compared to PBS controls.
• Histological Improvements: OSM treatment significantly reduced wound width (by 33%) and area (by 43%) while increasing dermal and epidermal thickness.
• Mechanistic Rescue:
  • Epithelialization: Significant increase in Ki67+ proliferating epidermal cells.
  • Angiogenesis: Significant increase in CD31+ capillary density.
  • Neurogenesis: Significant increase in βIII-tubulin+ axon density, indicating enhanced cutaneous axon regeneration.

5. Significance and Conclusion

• Pathophysiological Insight: The study establishes that Schwann cell dysfunction is a primary driver of impaired diabetic wound healing, specifically due to the failure of SCs to dedifferentiate, proliferate, and migrate into the wound bed.
• Therapeutic Potential: It identifies Oncostatin M as a potent therapeutic candidate. By bypassing the dysfunctional SCs and directly administering OSM, the study shows that the downstream effects on epithelial proliferation, angiogenesis, and nerve regeneration can be restored.
• Clinical Translation: Given that OSM is a known SC-secreted factor, this work suggests that chronic diabetic wounds could be treated by augmenting this specific paracrine pathway, offering a new strategy beyond standard growth factors or anti-inflammatory therapies.
• Novelty: This is the first report demonstrating that OSM promotes cutaneous axon regrowth in the context of diabetic wound healing, expanding the known role of OSM beyond its previously established roles in bone regeneration and itch sensation.

Limitations noted by authors: The study relies on a mouse model; future work is needed to confirm these findings in human clinical samples and to determine if similar mechanisms apply to other ulcer types (venous, arterial). Additionally, the upstream signals causing the initial SC dysfunction in diabetes require further definition.